CASI Pharmaceuticals Inc. [NASDAQ: CASI] closed the trading session at $1.92 on 08/04/20. The day’s price range saw the stock hit a low of $1.91, while the highest price level was $2.00. The company report on July 22, 2020 that CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.90 per share. CASI has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. The offering is expected to close on or about July 24, 2020, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $38.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.
Oppenheimer & Co. Inc. is acting as the sole bookrunning manager, and Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-manager, for the offering.
The stocks have a year to date performance of -37.86 percent and weekly performance of -3.52 percent. The stock has been moved at -30.31 percent over the last six months. The stock has performed -22.27 percent around the most recent 30 days and changed 15.66 percent over the most recent 3-months.
If compared to the average trading volume of 367.89K shares, CASI reached to a volume of 1419463 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about CASI Pharmaceuticals Inc. [CASI]:
Maxim Group have made an estimate for CASI Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 22, 2016. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $2.50 to $3. The new note on the price target was released on October 29, 2015, representing the official price target for CASI Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $2.50, while H.C. Wainwright analysts kept a Buy rating on CASI stock.
The Average True Range (ATR) for CASI Pharmaceuticals Inc. is set at 0.13, with the Price to Sales ratio for CASI stock in the period of the last 12 months amounting to 32.56. The Price to Book ratio for the last quarter was 2.70, with the Price to Cash per share for the same quarter was set at 0.43.
CASI stock trade performance evaluation
CASI Pharmaceuticals Inc. [CASI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.52. With this latest performance, CASI shares dropped by -22.27% in over the last four-week period, additionally sinking by -30.31% over the last 6 months – not to mention a drop of -35.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CASI stock in for the last two-week period is set at 36.44, with the RSI for the last a single of trading hit 35.56, and the three-weeks RSI is set at 40.43 for CASI Pharmaceuticals Inc. [CASI]. The present Moving Average for the last 50 days of trading for this stock 2.3766, while it was recorded at 1.9700 for the last single week of trading, and 2.5142 for the last 200 days.
CASI Pharmaceuticals Inc. [CASI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CASI Pharmaceuticals Inc. [CASI] shares currently have an operating margin of -968.07 and a Gross Margin at -32.78. CASI Pharmaceuticals Inc.’s Net Margin is presently recorded at -1114.31.
Return on Total Capital for CASI is now -38.67, given the latest momentum, and Return on Invested Capital for the company is -50.18. Return on Equity for this stock declined to -50.46, with Return on Assets sitting at -42.61. When it comes to the capital structure of this company, CASI Pharmaceuticals Inc. [CASI] has a Total Debt to Total Equity ratio set at 3.02. Additionally, CASI Total Debt to Total Capital is recorded at 2.93, with Total Debt to Total Assets ending up at 2.14. Long-Term Debt to Equity for the company is recorded at 1.40, with the Long-Term Debt to Total Capital now at 1.36.
Reflecting on the efficiency of the workforce at the company, CASI Pharmaceuticals Inc. [CASI] managed to generate an average of -$368,256 per employee. Receivables Turnover for the company is 6.39 with a Total Asset Turnover recorded at a value of 0.04.CASI Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.90.
Earnings per share (EPS) analysis for CASI Pharmaceuticals Inc. [CASI] stock
With the latest financial reports released by the company, CASI Pharmaceuticals Inc. posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -77.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CASI.
CASI Pharmaceuticals Inc. [CASI]: Insider Ownership positions
There are presently around $42 million, or 18.60% of CASI stock, in the hands of institutional investors. The top three institutional holders of CASI stocks are: IDG-ACCEL CHINA GROWTH FUND III ASSOCIATES L.P. with ownership of 7,973,536, which is approximately 0% of the company’s market cap and around 4.00% of the total institutional ownership; BLACKROCK INC., holding 3,251,569 shares of the stock with an approximate value of $6.24 million in CASI stocks shares; and VANGUARD GROUP INC, currently with $4.58 million in CASI stock with ownership of nearly 2.156% of the company’s market capitalization.
Positions in CASI Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 30 institutional holders increased their position in CASI Pharmaceuticals Inc. [NASDAQ:CASI] by around 1,661,209 shares. Additionally, 22 investors decreased positions by around 375,728 shares, while 12 investors held positions by with 19,695,501 shares. The mentioned changes placed institutional holdings at 21,732,438 shares, according to the latest SEC report filing. CASI stock had 8 new institutional investments in for a total of 1,385,374 shares, while 5 institutional investors sold positions of 79,100 shares during the same period.